Nuclear receptor binding agents
US9623021B2 · kind B2 · utility
3Cited by
41References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 4, 2010 |
| Grant date | Apr 18, 2017 |
| Priority date | — |
| Expiry date | Aug 22, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D217/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods for prevention and/or treatment of metabolic disorders, post-menopausal obesity and conditions associated with high fat diet consumption including, obesity, body weight gain, fat mass formation, bone mineral content reduction, white adipose tissue weight gain, increased cholesterol levels, increased leptin levels, insulin resistance, type II diabetes, increased blood glucose levels, inflammatory diseases, cardiovascular diseases, fatty liver condition (accumulation of fat in the liver), decreased uncoupling protein-1 (UCP-1) levels and increased lipogenesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.